Frontiers in Pharmacology (Apr 2018)

Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy

  • Javier Durán,
  • Manuel Estrada

DOI
https://doi.org/10.3389/fphar.2018.00381
Journal volume & issue
Vol. 9

Abstract

Read online

No abstracts available.

Keywords